Acute Myeloid Leukemia (AML)
Conditions
Interventions
Observation group:None
Sponsors
The Affiliated Hospital of Southwest Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >=18 years, any gender; 2. Diagnosed with newly diagnosed acute myeloid leukemia (excluding acute promyelocytic leukemia, M3) through bone marrow aspiration and biopsy according to WHO 2016/2022 diagnostic criteria. 3. Assessed to be suitable for venetoclax-based regimen treatment (including but not limited to: age =75 years, or unfit for intensive chemotherapy, or relapsed/refractory, but this study only includes newly diagnosed patients judged to be suitable for venetoclax). 4. Major organ functions (heart, liver, kidney) basically meet the requirements for venetoclax use. 5. Voluntarily signed informed consent form.
Exclusion criteria
Exclusion criteria: 1. Acute promyelocytic leukemia (APL, M3); 2. Previously received any anti-leukemia treatment for AML (including chemotherapy, targeted therapy, immunotherapy, etc.); 3. Concurrent active other malignancies; 4. Active severe infection, autoimmune disease, or known immunodeficiency; 5. Pregnant or breastfeeding women; 6. Simultaneous participation in other interventional clinical trials that may interfere with the results of this study; 7. Subjects deemed by the investigator as unable to complete follow-up or with poor compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bone marrow MDSC percentage;M-MDSC/PMN-MDSC Subpopulation Ratio;PD-L1 expression rate on MDSC surface; | — |
Countries
China
Contacts
Public ContactPengqiang Wu
The Affiliated Hospital of Southwest Medical University
Outcome results
None listed